NuVasive’s fourth quarter revenue jumped more than 10 percent, from $150 million to $165.8 million. Its year-end revenue also increased by nearly 15 percent from 2011, totaling $620 million from $540.5 million.
Some of the improvement can be tied to fewer fourth quarter operating expenses for impairment of goodwill and intangible assets, which the company spent $18 million on in 2011 and only $9.7 million on in 2012.
More Articles on Devices:
Amedica Artificial Disc Implant Granted Patent
Vexim Acquires Orthopedic Cement Injection Technology
MAKO Surgical Loses $5.7M in 4Q 2012 From Fewer Robotic Device Sales
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.